RNA vs MSFT: Which Stock is Better?
Side-by-side comparison of Atrium Therapeutics, Inc. Common Stock and Microsoft Corporation in 2026
RNA
Atrium Therapeutics, Inc. Common Stock
$13.80
MSFT
Microsoft Corporation
$498.10
Key Metrics Comparison
| Metric | RNA | MSFT | Winner |
|---|---|---|---|
| Market Cap | $217.50M | $3.71T | MSFT |
| P/E Ratio | N/A | 33.89 | RNA |
| EPS (TTM) | $N/A | $14.08 | MSFT |
| Revenue Growth | 14.0% | 18.4% | MSFT |
| Gross Margin | 0.0% | 67.9% | MSFT |
Analyze RNA
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is RNA or MSFT a better investment?
Comparing RNA and MSFT: Atrium Therapeutics, Inc. Common Stock has a market cap of $217.50M while Microsoft Corporation has $3.71T. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between RNA and MSFT?
RNA (Atrium Therapeutics, Inc. Common Stock) and MSFT (Microsoft Corporation) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: RNA or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: RNA or MSFT?
MSFT has higher revenue growth at 18.4% vs 14.0% for RNA.
Which company is more profitable: RNA or MSFT?
Microsoft Corporation (MSFT) has higher gross margins at 67.9% compared to 0.0% for RNA.
Which is the larger company: RNA or MSFT?
Microsoft Corporation (MSFT) is larger with a market cap of $3.71T compared to $217.50M for RNA.
Should I buy RNA or MSFT in 2026?
Both RNA and MSFT have investment merit. RNA trades at $13.80 while MSFT trades at $498.10. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between RNA and MSFT stock?
Key differences: Market Cap ($217.50M vs $3.71T), P/E Ratio (N/A vs 33.9x), Revenue Growth (14.0% vs 18.4%), Gross Margin (0.0% vs 67.9%).
Should I buy RNA or MSFT in 2026?
The choice between RNA and MSFT depends on your investment goals. MSFT shows higher revenue growth (18.4%). MSFT has better margins (67.9%). Consider your risk tolerance and time horizon.
What is the market cap comparison between RNA and MSFT?
RNA (Atrium Therapeutics, Inc. Common Stock) has a market cap of $217.50M, while MSFT (Microsoft Corporation) has a market cap of $3.71T. MSFT is the larger company by market value.